KAYO MOTOR
834058
Zhejiang Zoenn Design
300901
Zhejiang Meorient Commerce & Exhibition Inc.
300795
Fujian Zitian Media Technology
300280
Zhejiang Prulde Electric Appliance
301353
CN Stock MarketDetailed Quotes
002898 Sailong Pharmaceutical Group
- 11.97
- +0.08+0.67%
Market Closed Dec 13 15:00 CST
2.11BMarket Cap1330.00P/E (TTM)
12.19High11.76Low68.07KlotVolume11.89Open11.89Pre Close81.74MTurnover6.72%Turnover Ratio221.67P/E (Static)176.00MShares14.3352wk High3.98P/B1.21BFloat Cap7.6852wk Low13.08Limit Up101.26MShs Float30.73Historical High10.70Limit Down3.62%Amplitude7.42Historical Low0.02Dividend TTM12.01Avg Price27.74KlotAsk0.17%Div YieldTTM100Lot Size36.41KlotBid
Sailong Pharmaceutical Group News
Sailong Pharmaceutical Group (002898.SZ): Participating in the tenth batch of national Pharmaceutical centralized procurement, expected to win the bid.
On December 13, Glonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical (Changsha) Co., Ltd. (hereinafter referred to as "Changsha Sailong") participated in the bidding work organized by the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the tenth batch of national centralized procurement of pharmaceuticals. Some of the company's products are expected to win bids in this centralized procurement.
Sailong Pharmaceutical Group (002898.SZ) has obtained the supplementary approval letter for Pregabalin Capsules.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently received...
Sailong Pharmaceutical Group (002898.SZ): Sailong Polaris has cumulatively reduced its shareholding by 1%.
On November 4th, Geronghui reported that Sailong Pharmaceutical Group (002898.SZ) recently received a notification letter from shareholder Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., holding more than 5% of the shares, about the change in equity reaching 1%. It was learned that following the company's previous disclosure of the announcement of shareholders reducing their holdings by more than 1%, Sailong Juzhi reduced the company's shares by 130,000 shares through centralized auction trading from November 26, 2022, to November 28, 2022, between May 4, 2023, and June 2, 2023, through centralized auction trading.
Cailong Pharmaceuticals: Report for the third quarter of 2024
Sailong Pharmaceutical Gets Approval Notice for Fluorouracil Listing
Sailong Pharmaceutical Group (002898.SZ): Subsidiary has obtained the approval notice for the application for listing of chemical raw materials.
On September 25th, Gelonhui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the National Medical Products Administration's approval and issuance of the approval notice for the listing application of hydrochloride esmolol as an active pharmaceutical ingredient. The main indications for hydrochloride esmolol preparations are: used to treat paroxysmal supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension.
Sailong Pharmaceutical GroupLtd's (SZSE:002898) Promising Earnings May Rest On Soft Foundations
Sailong Pharmaceutical Unit's Omeprazole Gets API Listing Approval in China
Sailong Pharmaceutical Group (002898.SZ): Subsidiary obtained the approval notice for the market application of the chemical raw material drug Omeprazole Sodium.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the "Chemical Raw Materials Drug Market Application Approval Notice" for Omeprazole Sodium issued by the National Medical Products Administration. The main indications for Omeprazole Sodium formulation are duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome.
Cailong Pharmaceuticals: 2024 Semi-Annual Report Summary
Cailong Pharmaceuticals: Semi-Annual Report 2024
Sailong Pharmaceutical Group (002898.SZ): The net income in the first half of the year was 1.7647 million yuan, a year-on-year decrease of 40.93%.
On August 28, Gelonhui reported the 2024 interim report for sailong pharmaceutical group (002898.SZ), with operating revenue of 0.156 billion yuan, a year-on-year decrease of 0.46%; a net income attributable to the shareholders of the listed company of 1.7647 million yuan, a year-on-year decrease of 40.93%; a non-recurring net income attributable to the shareholders of the listed company of 1.3731 million yuan; and an earnings per share of 0.0100 yuan.
Sailong Pharmaceutical Group (002898.SZ) announced its performance for the first half of the year, with a net income of 1.7647 million yuan, a decrease of 40.93%.
Sailong Pharmaceutical Group (002898.SZ) released the semi-annual report for 2024, during the reporting period, the company achieved revenue...
Sailong Pharmaceutical Group (002898.SZ) has appointed Duan Daifeng as the company's vice president.
On July 19th, Gelonhui reported that Sailong Pharmaceutical Group (002898.SZ) announced the convening of the third meeting of the fourth board of directors on July 19, 2024, and approved the "Proposal on Appointing the Company's Vice President". Mr. Duan Daifeng was appointed as the company's vice president with the approval of the company's chairman, Mr. Cai Nangui, and the nomination committee of the board of directors. His term of office will be from the date of approval of this board of directors meeting to the expiration of the fourth board of directors.
Sailong Pharmaceutical's Anti-Cancer Chemotherapy Drug Gets Marketing Nod
Sailong Pharmaceutical Group (002898.SZ) received the approval notice for the application of market launch of the active pharmaceutical ingredient Fosaprepitant dimeglumine.
On July 1st, Gelunhui reported that Sailong Pharmaceutical Group (002898.SZ) announced its subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the "Chemical raw materials pharmaceutical application approval notice" for fosaprepitant dimeglumine issued by the National Medical Products Administration. Fosaprepitant dimeglumine is mainly used in combination with other antiemetic drugs for the prevention of acute and delayed nausea and vomiting in children over 6 months and adult patients with highly emetogenic antitumor chemotherapy drugs (HEC), including high-dose cisplatin, during initial and repeated use.
Sailong Pharmaceutical Group (002898.SZ) plans to distribute 0.2 yuan per share on a basis of 10 shares, with ex-right and ex-dividend dates on June 28.
Sailong Pharmaceutical Group (002898.SZ) announced its annual equity distribution for 2023: it plans to distribute 1.2 yuan in cash for every 10 shares to all shareholders...
Cailong Pharmaceutical (002898.SZ): Obtained a notice of approval for the marketing application of the chemical raw material propofol tenofovir fumarate
On June 3, Gelonghui Pharmaceutical (002898.SZ) announced that Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the approval and issuance of the “Notice of Approval for the Marketing Application of Propofol fumarate Tenofovir” by the State Drug Administration. The main indications for prophenol tenofovir fumarate are: It is used to treat chronic hepatitis B in adults and adolescents.
Cailong Pharmaceutical (002898.SZ): Lysapirine received a notice of approval for the marketing application of chemical raw materials
Gelonghui, May 24 | Sailong Pharmaceutical (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for lysapillin approved and issued by the State Drug Administration. The main indications for lysapirine are: it is used to treat fever and mild to moderate pain.
Sailong Pharmaceutical (002898.SZ): Net profit of 16.241 million yuan in the first quarter decreased by 49.21% year on year
Gelonghui, April 19 | Sailong Pharmaceutical (002898.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 694.844 million yuan, down 12.52% year on year; net profit attributable to shareholders of listed companies was 1.6241 million yuan, down 49.21% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8603 million yuan, down 8.28% year on year; basic earnings per share were 0.0092 yuan